| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |





From the Departments of Neurosciences* and Cell Biology,
The Lerner Research Institute, and the Department of Neurology,
the Mellen Center for Multiple Sclerosis Treatment and Research, the Cleveland Clinic Foundation, Cleveland, Ohio; Berlex Biosciences,
Richmond, California; the Department of Pathology,
University of California, San Francisco, California; the Department of Neurology,¶ The Johns Hopkins University, Baltimore, Maryland; the Department of Neurology, || Mayo Clinic, Rochester, Minnesota; and the Brain Research Institute,** University of Vienna, Vienna, Austria
CC chemokine receptor 8 (CCR8) has been detected in vitro on type 2 helper and regulatory lymphocytes, which might exert beneficial functions in multiple sclerosis (MS) and on macrophages and microglia, possibly promoting tissue injury in MS lesions. To discriminate the relevant expression pattern in vivo, we defined the cell types that expressed CCR8 in MS lesions and determined the relationship of CCR8 expression and demyelinating activity. CCR8 was not expressed on T cells but was associated with phagocytic macrophages and activated microglia in MS lesions and directly correlated with demyelinating activity. To identify factors associated with CCR8 expression, the study was extended to other central nervous system (CNS) pathologies. CCR8 was consistently expressed on phagocytic macrophages and activated microglia in stroke and progressive multifocal leukoencephalopathy, but not expressed on microglia in pathologies that lacked phagocytic macrophages such as senile change of the Alzheimers type. CCR8 was up-regulated by macrophage differentiation and activating stimuli in vitro. In summary CNS CCR8 expression was associated with phagocytic macrophages and activated microglial cells in human CNS diseases, suggesting that CCR8 may be a feasible target for therapeutic intervention in MS. CCR8 expression may also indicate a selective program of mononuclear phagocyte gene expression.
This article has been cited by other articles:
![]() |
S. Sinha, S. Subramanian, T. M. Proctor, L. J. Kaler, M. Grafe, R. Dahan, J. Huan, A. A. Vandenbark, G. G. Burrows, and H. Offner A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS J. Neurosci., November 14, 2007; 27(46): 12531 - 12539. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cantor and K. Haskins Recruitment and Activation of Macrophages by Pathogenic CD4 T Cells in Type 1 Diabetes: Evidence for Involvement of CCR8 and CCL1 J. Immunol., November 1, 2007; 179(9): 5760 - 5767. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Jensen, R. Nygaard, S. Thiele, A. Elder, G. Zhu, R. Kolbeck, S. Ghosh, T. W. Schwartz, and M. M. Rosenkilde Molecular Interaction of a Potent Nonpeptide Agonist with the Chemokine Receptor CCR8 Mol. Pharmacol., August 1, 2007; 72(2): 327 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Dewin, J. Catusse, and U. A. Gompels Identification and Characterization of U83A Viral Chemokine, a Broad and Potent {beta}-Chemokine Agonist for Human CCRs with Unique Selectivity and Inhibition by Spliced Isoform J. Immunol., January 1, 2006; 176(1): 544 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Qu, E. W. Edwards, F. Tacke, V. Angeli, J. Llodra, G. Sanchez-Schmitz, A. Garin, N. S. Haque, W. Peters, N. van Rooijen, et al. Role of CCR8 and Other Chemokine Pathways in the Migration of Monocyte-derived Dendritic Cells to Lymph Nodes J. Exp. Med., November 15, 2004; 200(10): 1231 - 1241. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Ruffini, A. Biragyn, M. Coscia, L. K. Harvey, S.-C. Cha, B. Bogen, and L. W. Kwak Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis J. Leukoc. Biol., July 1, 2004; 76(1): 77 - 85. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |